About 38,288 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  11,950 results

Novel insights on 1,2oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leuk...
Drug Development Research; Labbozzetta M, Barreca M et. al.

Jun 25th, 2022 - A series of [1,2]oxazolo[5,4-e]isoindole derivatives was evaluated against HL-60 cell line and its multidrug resistance (MDR) variant, HL-60R, resistant to doxorubicin and to other P-gp substrates by overexpressing the efflux pump. They displayed ...

Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.
Expert Opinion on Emerging Drugs; Thomas X, Elhamri M et. al.

Jun 25th, 2022 - Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk profile, and in the relapsed/refractory setting...

A multiparametric niche-like drug screening platform in acute myeloid leukemia.
https://doi.org/10.1038/s41408-022-00689-3 10.1158/2159-8290.CD-19-1011 10.1056/NEJMoa1516192 10.1182/blood.2019003988 10.1158/2159-8290.CD-13-0350 10.1038/ng.3371 10.1038/s41586-018-0623-z 10.5966/sctm.2013-0166 10.1182/blood-2015-07-655860 10.1016/j.cell.2017.03.023 10.1126/sciadv.aau7314 10.1007/s00726-016-2215-2 10.1038/nature22993 10.1016/j.cell.2019.01.031 10.1182/blood-2015-11-683649 10.1038/nature20598 10.1182/blood-2016-09-738070 10.1093/bioinformatics/btv723 10.1182/blood.2018862383 10.1200/JCO.2016.67.1875 10.1056/NEJMc1509584 10.1038/leu.2013.338 10.1016/j.leukres.2019.106269 10.1158/2159-8290.CD-16-0237 10.1158/2159-8290.CD-16-0313 10.1016/j.stem.2012.12.013 10.1126/scitranslmed.3000349 10.1182/blood-2014-11-612416 10.1016/S0899-9007(98)00179-8 10.1038/bjc.2017.316 10.1016/j.cyto.2012.12.023 10.1182/bloodadvances.2017007856 10.1016/j.leukres.2008.06.028 10.3324/haematol.2019.236810 10.1111/bjh.13516 10.1158/0008-5472.CAN-12-1906 10.1016/S2352-3026(17)30208-9 10.1016/j.leukres.2017.11.008 10.1016/j.ccell.2019.06.003 10.3324/haematol.2019.240705 10.1038/s41375-018-0327-2 10.1182/blood-2016-03-703868 10.1038/s43018-021-00177-w 10.1038/s41586-020-2864-x 10.1016/j.ccr.2014.01.031 10.1038/nature13034 10.1016/j.leukres.2018.11.006 10.1002/JLB.5A0220-676RR 10.1111/bjh.16432 10.1111/bjh.16684 10.1172/JCI133344 10.1038/s41591-020-1089-8 10.1182/blood-2016-02-699363 10.1097/HS9.0000000000000310 10.1182/bloodadvances.2019001364 10.1038/leu.2017.276 10.1038/s41408-020-0330-5 10.1182/blood-2016-08-733196
Blood Cancer Journal; Dal Bello R, Pasanisi J et. al.

Jun 25th, 2022 - Functional precision medicine in AML often relies on short-term in vitro drug sensitivity screening (DSS) of primary patient cells in standard culture conditions. We designed a niche-like DSS assay combining physiologic hypoxia (O2 3%) and mesench...

see more →

Guidelines  12 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  30 results see all →

Clinicaltrials.gov  1,665 results

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the safety and maximum tolerable dose (MTD) of liposomal cytarabine and daunorubicin (CPX-351) in combination with quizartinib in patients with newly diagnosed or relapsed refractory acute myeloid leukemia (AML)...

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Jun 24th, 2022 - Severe aplastic anemia (SAA) is a life-threatening bone marrow failure characterized by pancytopenia and a hypocellular marrow. Allogeneic bone marrow transplantation is curative in younger patients, but older age and/or lack of a suitable donor h...

CHIP/CCUS Natural History Protocol

Jun 24th, 2022 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...

Optimizing PTCy Dose and Timing

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Jun 24th, 2022 - This is a Phase 1/2, open-label, multi-center, non-randomized, 2-part study in patients with refractory and relapsed AML and refractory myelodysplastic syndrome. Study AB18001 has a multi-stage design. The first part is a dose escalation study tha...

see more →

News  1,652 results

No Survival Gain From High-Dose Cytarabine Consolidation in AML

Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...

Adverse-Risk Acute Myeloid Leukemia

Jun 16th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, I'm a professor of medicine. I run the leukemia program at Weill Cornell Medicine at the NewYork-Presbyterian Hospital in New York City. It is ...

Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML

Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML

Jun 12th, 2022 - Older, fit patients with acute myeloid leukemia (AML) pretreated with a 10-day regimen of decitabine (Dacogen) prior to allogeneic hematopoietic stem cell transplantation had similar overall survival compared with those receiving conventional inte...

Intermediate-Risk Acute Myeloid Leukemia

May 19th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

see more →

Patient Education  6 results see all →